Therapies based on incretin and employing ―glucagon-like peptide-1 receptor agonists (GLP1RA)‖ are already well-established in the ―treatment of type 2 diabetes (T2D)‖. In order to target several metabolic pathways for the ―metabolism of carbohydrates, lipids, and proteins, novel dual- or triple-receptor agonists‖ that bind to the receptors for ―glucagon, glucosedependent insulinotropic polypeptide (GIP), and/or GLP-1‖ concurrently are being developed. ―Dual- and triple-receptor agonists‖ that act via various receptors and post receptor pathways seem promising for the treatment of type 2 diabetes (T2D) and obesity due to the possibility of additive or synergistic effects. A critical turning point in this process was the recent approval of the first dual-receptor agonist. The ―Food and Drug Administration (FDA)‖ in the US approved tirzepatide, a ―GIP/GLP-1‖ receptor agonist, for once-weekly subcutaneous injections as a T2D treatment in May 2022. A recent approval from the ―European Medicines Agency (EMA)‖. It has been established that tirzepatide has stronger effects on decreasing these parameters than traditional anti-diabetic medication and that its dose-dependent effects result in clinically meaningful decreases in body weight and glycemic indices. In this article, tirzepatide's potential applications for the treatment of obesity and maybe other T2D comorbidities are summarised together with the present clinical study programme, its findings, and related clinical trial applications.